Is MiNK Therapeutics, Inc. (INKT) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 10.2% / 30% | 9.5% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 10.2% / 33% | 9.5% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 86.1% / 33% | 80.0% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 10.2% / 33% | 9.5% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 86.1% / 33% | 80.0% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -69.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$10M |
| Free Cash Flow | -$10M |
| Total Debt | $5M |
| Current Ratio | 1.1 |
| Total Assets | $6M |
Price & Trading
| Last Close | $9.63 |
| 50-Day MA | $11.02 |
| 200-Day MA | $13.03 |
| Avg Volume | 294K |
| Beta | 0.4 |
|
52-Week Range
$6.34
| |
About MiNK Therapeutics, Inc. (INKT)
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab plus balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastro-esophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome. It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for auto-immune diseases. The company has collaborations with Autonomous Therapeutics to target and treat metastatic tumors; ImmunoScape, Inc. to discover and develop T-cell receptor therapies against targets in solid tumors; and C-Further for the development of PRAME-targeted iNKT cell therapy for pediatric cancers. The company was formerly known as AgenTus Therapeutics, Inc. and changed its name to MiNK Therapeutics, Inc. in June 2021. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is MiNK Therapeutics, Inc. (INKT) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), MiNK Therapeutics, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is MiNK Therapeutics, Inc.'s debt ratio?
MiNK Therapeutics, Inc.'s debt ratio is 10.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 86.1%.
What are MiNK Therapeutics, Inc.'s key financial metrics?
MiNK Therapeutics, Inc. has a market capitalization of $52M.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.